Acute septic cardiomyopathy;AKUTE SEPTISCHE KARDIOMYOPATHIE

Internist

Volumn 39, Issue 5, 1998, Pages 467-478

  Muller Werdan U ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOLAMINE; DEXAMETHASONE; DOPAMINE; DOPEXAMINE; GLUCOCORTICOID; IMMUNOGLOBULIN; INOTROPIC AGENT; NORADRENALIN; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE AGENT;

CARDIOMYOPATHY; CLINICAL FEATURE; HEART RIGHT VENTRICLE FUNCTION; HUMAN; INTENSIVE CARE; MULTIPLE ORGAN FAILURE; PATHOGENESIS; PROGNOSIS; SHORT SURVEY; VASODILATATION;

CARDIOMYOPATHIES; HEART; HEMODYNAMIC PROCESSES; HUMANS; INTENSIVE CARE; MICROCIRCULATION; MULTIPLE ORGAN FAILURE; PROGNOSIS; SHOCK, SEPTIC; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031751392     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001080050198     Document Type: Short Survey

References (39)

1. American College of Chest Physicians/Society of Critcal Care Medicine Consensus Conference Committee (1992) American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and multiple organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864-874
2. Bone R (1996) Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 24:1125-1128
3. Coalition for Critical Care Excellence (1995) Standards of evidence for the safety and effectiveness of critical care monitoring devices and related interventions. Crit Care Med 23:1756-1763
4. Connors AF, Speroff T, Dawson NV, Thomas C, Harrell FE, Wagner D, Desbiens N, Goldman L, Wu AW, Califf RM, Fulkerson WJ, Vidaillet H, Broste S, Bellamy P, Lynn J, Knaus WJ for the SUPPORT Investigators (1996) The effectiveness of right heart catheterization in the initial care of critically ill patients. JAMA 276:889-897
5. Dalen JE, Bone RC (1996) Is it time to pull the pulmonary artery catheter? JAMA 276:916-918
6. Day NPJ, Phu NH, Bethell DR Mai NTH, Chau TTH, Hien TT, White NJ (1996) The effects of dopamine and adrenaline infusions on acid-base balance and systemic haemodynamics in severe infection. Lancet 348:219-223
7. Fang K, Krahmer RL, Rypins EB, Law WR (1996) Starling resistor effects on pulmonary artery occlusion pressure in endotoxin shock provide inaccuracies in left ventricular compliance assessments. Crit Care Med 24:1618-1625
8. Hallström S, Bernhart E, Müller U, Fürst W, Vogl C, Koidl B, Werdan K, Schlag G (1994) A cardio-depressant factor (CDF) isolated from hemofiltrates of patients in septic and/or cardiogenic shock blocks calcium inward current in cardiomyocytes. Shock 2, Suppl:15
9. 2+-current in cardiomyocytes. Am J Physiol 260:H869-H876
10. Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo JE (1996) Tumor necrosis factor a and interleukin 1β are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 183:949-958
11. Marecaux G, Pinsky MR, Dupont E, Kahn RJ, Vincent J-L (1996) Blood lactate levels are better prognostic indicators than TNF and IL-6 levels in patients with septic shock. Intensive Care Med 22:404-408
12. Maynard ND, Bihari DJ, Dalton R, Smithies MN, Mason RC (1995) Increasing splanchnic blood flow in the critically ill. Chest 108:1648-1654
13. Müller-Höcker J, Haerty W (1993) Pathomorphological aspects of the heart in septic patients. In: Schlag G, Redl H (eds) Pathophysiology of shock, sepsis, and organ failure. Springer, Berlin Heidelberg New York, S853-858
14. Müller-Werdan U, Kuhn C, Heinroth K, Prondzinsky R, Loppnow H, Schumann H, Darmer D, Holtz J, Werdan K (1997) Die akute septische Kardiomyopathie. Intensivmed 34:333-351
15. Müller-Werdan U, Prondzinsky R, Witthaut R, Stache N, Heinroth K, Kuhn C, Schmidt H, Busch I, Werdan K (1997) Das Herz bei Sepsis und MODS. Wien Klin Wochenschr 109 (Suppl 1):3-24
16. Müller-Werdan U, Reithmann C, Werdan K (1996) Cytokines and the heart: Molecular mechanisms of septk cardiomyopathy. R.G. Landes Company, Georgetown USA/Chapman & Hall, New York USA/Springer Heidelberg
17. Müller-Werdan U, Schumann H, Fuchs R, Reithmann C, Loppnow H, Koch S, Zimny-Arndt U, Chang He, Darmer D, Jungblut P, Stadler J, Holtz J, Werdan K (1997) Tumor necrosis factor a (TNFα) is cardiodepressant in pathophysiologically relevant concentrations without inducing inducible nitric oxide-(NO)-synthase (iNOS) or triggering serious cytotoxicity. J Mol Cell Cardiol 29:2915-2923
18. Müller-Werdan U, Schumann H, Loppnow H, Fuchs R, Darmer D, Stadler J, Holtz J, Werdan K (1998) Endotoxin and tumor necrosis factor α exert a similar proinflammatory effect in neonatal rat cardiomyocytes, but have different cardiodepressant profiles. J Mol Cell Cardiol, im Druck
19. Niemer M, Nemes C, Lundsgaard-Hansen P, Blauhut B (1992) Datenbuch Intensivmedizin (Datenbuch Anästhesiologie und Intensivmedizin, Bd 2). Fischer, Stuttgart Jena New York
20. Parrillo JE (1989) The cardiovascular pathophysiology of sepsis. Ann Rev Med 40:469-485
21. Pilz G, McGinn P, Boekstegers P, Kääb S, Weidenhöfer S, Werdan K (1994) Pseudomonas sepsis does not cause more severe cardiovascular dysfunction in patients than non-Pseudomonas sepsis. Circ Shock 42:174-182
22. Prondzinsky R, Lehmann D, Witthaut R, Stabenow I, Redling F, Cichon R, Zerkowski H-R, Teichmann W, Werdan K (1997) Volumen und kardiogener Schock. Journal für Anästhesie und Intensivbehandlung 4:14-23
23. Prondzinsky R, Müller-Werdan U, Pilz G, Witthaut R, Stabenow I, Werdan K, Zerkowski H-R (1997) Systemische Entzündungsreaktion extrakorporaler Therapieverfahren (II): Der cardiopulmonale Bypass. Wien Klin Wochenschr 109/110:346-353
24. Prondzinsky R, Stache N, Witthaut R, Winkler M, Fraunberger P, Walli AK, Seidel D, Werdan K (1997) Multiorganversagen (MOV) mit und ohne Sepsis - Inzidenz supra- und ventrikulärer Arrhythmien. Wien Klin Wochenschr 109(Suppl 1):FV13
25. Raper R, Sibbald WJ, Driedger AA, Gerow K (1989) Relative myocardial depression in normotensive sepsis. J Crit Care 4:9-18
26. Reinhart K, Bloos F, Spies C (1995) Vasoactive drug therapy in sepsis. In: Sibbald WJ, Vincent J-L (Hrsg) Clinical Trials for the Treatment of Sepsis (Update in Intensive Case and Emergency Medicine 19;Vincent J-L, series editor). Springer, Berlin Heidelberg, S 207-224
27. Romberg E (1921) Die septische akute Myokarditis. In: Romberg E (Hrsg) Lehrbuch der Krankheiten des Herzens und der Blutgefäße. Ferdinand Enke, Stuttgart, 3. Auflage, S 494
28. Rudis MI Basha MA, Zarowitz BJ (1996) Is it time to reposition vasopressors and inotropes in sepsis? Crit Care Med 24:525-537
29. Sakka SG, Reinhart K (1996) Volumentherapie im septischen Schock. Intensiv- und Notfallbehandlung 21:73-79
30. Schuster H-P (1989) VI. Schlußfolgerungen. In: Werdan K, Schuster H-P, Schlag G, Spilker G, Neumann R (Hrsg) Sepsis:Toxinwirkung, Herzschädigung, Quantifizierung, supportive Therapie mit Immunglobulinen. Intensimed 26 (Suppl 1):152-153
31. Smail N, Descorps Declere A, Duranteau J, Vigue B, Samii K (1996) Left ventricular function after severe trauma. Intensive Care Med 22:439-442
32. Thijs LG (1995) Fluid therapy in septic shock. In: Sibbald WJ, Vincent J-L (eds) Clinical trials for the treatment of Sepsis (Update in intensive care and emergency medicine 19, Vincent J-L, series editor). Springer, Berlin Heidelberg, S 167-190
33. Vincent J-L, Gris P, Coffernils M, Leon M, Pinsky M, Reuse C, Kahn RJ (1992) Myocardial depression characterizes the fatal course of septic shock. Surgery 111:660-667
34. Vincent J-L, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 22:707-710
35. Werdan K (1995) Towards a more causal treatment of septic cardiomyopathy. In: Vincent J-L (ed) Yearbook of intensive care and emergency medicine 1995. Springer, Berlin Heidelberg New York Tokyo, pp 518-538
36. Werdan K (1996) Prophylaxe und Therapie der akuten septischen Kardiomyopathie. In: Schuster H-P (Hrsg) Intensivtherapie bei Sepsis und Multiorganversagen. Springer, Berlin Heidelberg New York, S 200-248
37. Werdan K (1997) Die akute septische Kardiomyopathie - wird sie in ihrer Bedeutung unterschätzt? Intensivmed 34:326-328 (Editorial)
38. Werdan K, Reithmann C (1992) Differentialtherapie mit Katecholaminen. ln: Schüttler J, Schwilden H, Lauven PM (Hrsg) Klinische Pharmakologie und rationale Arzneimitteltherapie-Symposium, Bonn 1990. G. Thieme Verlag, Stuttgart New York, S 133-143
39. Witthaut R, Werdan K (1996) Ergebnisforschung am Beispiel der Sepsis. Internist 37:1249-1259